Osteocyte Communication Biomarkers in Bone Health

Abstract

Osteocyte communication plays a pivotal role in maintaining bone health, with biomarkers reflecting the dynamic state of bone remodeling and pathophysiology of metabolic bone diseases. Recent research has highlighted the importance of osteocyte-derived signaling molecules, such as sclerostin, DMP1, and FGF23, as potential biomarkers for clinical assessment, risk stratification, and therapeutic monitoring in disorders like osteoporosis and chronic kidney disease-mineral and bone disorder (CKD-MBD). This article reviews the current scientific evidence, clinical relevance, and practical implications of osteocyte communication biomarkers, offering insights into their mechanisms, diagnostic utility, and integration into guideline-based management.

Introduction

Osteocytes, the most abundant cells in bone tissue, are central regulators of skeletal homeostasis, orchestrating bone remodeling through intricate intercellular communication networks. These networks rely on the secretion of signaling molecules that modulate osteoblast and osteoclast activity, thereby influencing bone formation and resorption. The disruption of osteocyte signaling is increasingly recognized as a primary contributor to metabolic bone diseases, making osteocyte-derived biomarkers critical for understanding disease pathogenesis and improving clinical outcomes. This review provides a comprehensive overview of the molecular underpinnings, clinical applications, and future directions for osteocyte communication biomarkers in bone health.

Epidemiology / Disease Burden

Bone-related disorders, particularly osteoporosis, represent a significant global health burden, affecting over 200 million individuals worldwide. Osteoporotic fractures lead to substantial morbidity, mortality, and healthcare costs, particularly among postmenopausal women and the elderly. CKD-MBD further complicates bone health in patients with chronic kidney disease, increasing fracture risk and cardiovascular complications. The growing recognition of osteocyte dysfunction in these conditions underscores the necessity for sensitive and specific biomarkers to facilitate early diagnosis, risk stratification, and monitoring of therapeutic efficacy.

Pathophysiology

Osteocytes derive from osteoblasts that become embedded within the bone matrix, where they form an extensive lacuno-canalicular network. Through mechanotransduction, osteocytes sense mechanical strain and orchestrate bone remodeling via paracrine and endocrine signaling. Key molecules include sclerostin, which inhibits Wnt/β-catenin signaling and suppresses bone formation; DMP1, essential for mineralization and phosphate homeostasis; and FGF23, which regulates phosphate excretion and vitamin D metabolism. Aberrant expression or activity of these molecules disrupts bone turnover, leading to osteopenia, osteoporosis, or osteosclerosis, depending on the underlying pathology.

Risk Factors

Risk factors for osteocyte dysfunction and altered biomarker profiles include advancing age, postmenopausal estrogen deficiency, glucocorticoid therapy, chronic kidney disease, diabetes mellitus, immobilization, and genetic disorders affecting bone metabolism. Environmental influences such as inadequate nutrition, physical inactivity, and smoking can further modulate osteocyte signaling, exacerbating skeletal fragility. Understanding these risk factors is crucial for identifying individuals who may benefit from biomarker-based monitoring and tailored interventions.

Clinical Features

While osteocyte dysfunction itself is subclinical, its consequences manifest as reduced bone mineral density, impaired bone quality, and increased fracture risk. Clinically, patients may present with fragility fractures, vertebral compression, bone pain, or skeletal deformities. In CKD-MBD, osteocyte-derived FGF23 elevation can contribute to vascular calcification and cardiovascular morbidity. The detection of altered biomarker levels may precede clinical manifestations, providing an opportunity for early intervention and prevention of irreversible skeletal damage.

Diagnosis

Measurement of osteocyte communication biomarkers is emerging as a valuable adjunct to conventional diagnostic tools such as bone mineral density (BMD) assessment by dual-energy X-ray absorptiometry (DXA). Serum sclerostin, DMP1, and FGF23 concentrations can be quantified using validated immunoassays, with elevated sclerostin linked to low bone turnover and increased fracture risk, while dysregulated FGF23 is a hallmark of CKD-MBD. Combining biomarker profiles with clinical risk assessment models enhances diagnostic accuracy, enabling personalized management strategies.

Treatment & Management

Therapeutic interventions targeting osteocyte signaling pathways are transforming the management of metabolic bone diseases. Antisclerostin monoclonal antibodies, such as romosozumab, promote bone formation and increase BMD, demonstrating efficacy in reducing fracture risk in postmenopausal osteoporosis. Management of CKD-MBD involves modulation of FGF23, phosphate binders, and vitamin D analogs to restore mineral homeostasis. Regular monitoring of osteocyte biomarkers can guide therapeutic adjustments, optimize treatment response, and minimize adverse effects.

Recent Advances / Emerging Therapies

Recent advances in osteocyte biology have fueled the development of novel therapeutic agents and biomarker discovery platforms. Next-generation sequencing and proteomic analyses are uncovering new osteocyte-secreted factors with potential clinical relevance. Emerging therapies targeting DMP1, FGF23, and other signaling molecules hold promise for treating rare bone disorders and improving skeletal outcomes in high-risk populations. Advances in point-of-care biomarker assays are enhancing the feasibility of integrating osteocyte biomarker monitoring into routine clinical practice.

Guideline Recommendations

Current clinical guidelines from organizations such as the International Osteoporosis Foundation and Kidney Disease: Improving Global Outcomes (KDIGO) increasingly recognize the role of osteocyte-derived biomarkers in risk assessment and therapeutic decision-making. Recommendations emphasize the utility of sclerostin and FGF23 measurements in selected patient populations, particularly those with refractory osteoporosis or CKD-MBD. Ongoing research is anticipated to further refine guideline algorithms and expand the indications for biomarker-based management.

Conclusion

Osteocyte communication biomarkers represent an evolving frontier in bone health assessment, offering mechanistic insights, improved risk stratification, and opportunities for precision medicine in metabolic bone diseases. Integration of these biomarkers into clinical workflows has the potential to enhance patient outcomes, guide individualized therapy, and inform future research directions. Continued advances in biomarker discovery, assay technologies, and translational research will further solidify the central role of osteocyte signaling in the prevention and management of skeletal disorders.